Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study
This study demonstrated the PK equivalence of the two drugs and confirmed that both were well-tolerated.
Authors
- Yerong Yu (ORCID: https://orcid.org/0000-0003-0103-0087)
- Ting Li (ORCID: https://orcid.org/0000-0002-3732-6165)
- Hongling Yu
- Hui Liu (ORCID: https://orcid.org/0000-0002-9352-3358)
- Jingfang Sun
- Xinlei Chen (ORCID: https://orcid.org/0000-0003-3570-588X)
- Haiyan Cao (ORCID: https://orcid.org/0000-0001-9163-1497)
Institutions
- Sichuan University (CN)
- West China Medical Center of Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- China Shenhua Energy (China) (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/dddt.s500347
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00